Marisa Lima

Marisa Lima

Auto-generated profile, based on publicly available information

Marisa Lima

Centro Hospitalar e Universitário de Coimbra

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Experimental Gerontology
Verified
Journal Article
Closed access
AFAndreia Fernandes
Andreia Fernandes
MTMiguel Tábuas-Pereira
Miguel Tábuas-Pereira
DDDiana Duro
Diana Duro
MLMarisa Lima
Marisa Lima
HGHelena Gens
Helena Gens
ISIsabel Santana
Isabel Santana

20 March 2023 in European Journal of Neurology
Verified
Journal Article
Open access
ASAnuschka Spínola
Anuschka Spínola
MLMarisa Lima
Marisa Lima
MLMaria João Leitão
Maria João Leitão
CBCatarina Bernardes
Catarina Bernardes
JDJoão Durães
João Durães
IBInês Baldeiras
Inês Baldeiras
Background and purpose: Blood‐based biomarkers are promising tools for the diagnosis of Alzheimer disease (AD) at prodromal stages (mild cognitive impairment [MCI]) and are hoped to be implemented as screening tools for patients with cognitive complaints. In this work, we evaluated the potential of peripheral neurological biomarkers to predict progression to AD dementia and the relation between blood and cerebrospinal fluid (CSF) AD markers in MCI patients referred from a general neurological department.Methods: A group of 106 MCI patients followed at the Neurology Department of Coimbra University Hospital was included. Data regarding baseline neuropsychological evaluation, CSF levels of amyloid β 42 (Aβ42), Aβ40, total tau (t‐Tau), and phosphorylated tau 181 (p‐Tau181) were available for all the patients. Aβ42, Aβ40, t‐Tau, p‐Tau181, glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) levels were determined in baseline stored serum and plasma samples by commercial SiMoA (Single Molecule Array) assays. Progression from MCI to AD dementia was assessed at follow‐up (mean = 5.8 ± 3.4 years).Results: At baseline, blood markers NfL, GFAP, and p‐Tau181 were significantly increased in patients who progressed to AD at follow‐up (p < 0.001). In contrast, plasma Aβ42/40 ratio and t‐Tau showed no significant differences between groups. NfL, GFAP, and p‐Tau181 demonstrated good diagnostic accuracy to identify progression to AD dementia (area under the curve [AUC] = 0.81, 0.80, and 0.76, respectively), which improved when combined (AUC = 0.89). GFAP and p‐Tau181 were correlated with CSF Aβ42. Association of p‐Tau181 with NfL was mediated by GFAP, with a significant indirect association of 88% of the total effect.Conclusions: Our findings highlight the potential of combining blood‐based GFAP, NfL, and p‐Tau181 to be applied as a prognostic tool in MCI.

26 June 2020 in Journal of Neuropsychology
Verified
Journal Article
Closed access
PDF file
LALuísa Alves
Luísa Alves
SCSandra Cardoso
Sandra Cardoso
DSDina Silva
Dina Silva
TMTiago Mendes
Tiago Mendes
João MarôcoJoão Marôco
João Marôco
MGManuela Guerreiro
Manuela Guerreiro

13 May 2021 in Applied Neuropsychology: Adult
Verified
Journal Article
Closed access
MLMarisa Lima
Marisa Lima
ÉBÉlia Baeta
Élia Baeta
DDDiana Duro
Diana Duro
MTMiguel Tábuas-Pereira
Miguel Tábuas-Pereira
DVDaniela Valério
Daniela Valério
ISIsabel Santana
Isabel Santana
The Toulouse-Piéron Cancelation Test (TP) is a classic psychometric tool for the assessment of selective/sustained attention, processing speed and visuo-perceptual abilities. It is commonly used in neurological disorders such as epilepsy, multiple sclerosis or Alzheimer’s disease. It encompasses two main indexes: Work-Efficiency (WE) and Dispersion-Index (DI). The aim of this study is to provide normative scores for the TP in a sample of Portuguese healthy adults. The TP was administered to a convenience sample of 357 cognitively-dwelling subjects aged between [45 and 86] years old, following a standard assessment protocol. The normative scores were adjusted for age and education. Education was the main predictor of TP-WE (R2 = .310), whereas the influence of age on this score was lower (R2 = .191). These two variables explained 50.1% of the variance of the results. Regarding TP-DI, education was also the main predictor of the results (R2 = .039), whereas age was responsible for R2 = .011 and together, they explained 5% of the variance of TP-DI. TP performances are strongly influenced by age and education. This is the first study focused on the establishment of normative data after the age of 45 in the Portuguese population, allowing a reliable assessment in both clinical and research contexts.

Verified
Journal Article
Open access
PDF file
MAMaria Rosário Almeida
Maria Rosário Almeida
MTMiguel Tábuas-Pereira
Miguel Tábuas-Pereira
IBInes Baldeiras
Ines Baldeiras
MLMarisa Lima
Marisa Lima
JDJoão Durães
João Durães
ISIsabel Santana
Isabel Santana
In Portugal, heterozygous loss-of-function mutations in the progranulin (GRN) gene account for approximately half of the genetic mediated forms of frontotemporal dementia (FTD). GRN mutations reported thus far cause FTD through a haploinsufficiency disease mechanism. Herein, we aim to unveil the GRN mutation spectrum, investigated in 257 FTD patients and 19 family members from the central/north region of Portugal using sequencing methods. Seven different pathogenic variants were identified in 46 subjects including 40 patients (16%) and 6 relatives (32%). bvFTD was the most common clinical presentation among the GRN mutation patients, who showed a global pattern of moderate-to-severe frontotemporoparietal deficits in the neuropsychological evaluation. Interestingly, two mutations were novel (p.Thr238Profs*18, p.Leu354Profs*16), and five were previously described, although three of them only in the Portuguese population, suggesting a population-specific GRN mutational spectrum. The subjects harboring a GRN mutation showed a significant reduction in serum PGRN levels, supporting the pathogenic nature of these variants. This work broadens the mutation spectrum of GRN and the identification of the underlying GRN mutations provided an accurate genetic counselling and allowed the enrolment of subjects with GRN mutations (both asymptomatic and symptomatic) in ongoing clinical trials, which is essential to test new drugs for the disease.

13 January 2022 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
DVDaniela Valério
Daniela Valério
JAJorge Almeida
Jorge Almeida
NDNele Demeyere
Nele Demeyere
MLMarisa Lima
Marisa Lima
JNJoana Nogueira
Joana Nogueira
ISIsabel Santana
Isabel Santana